Murat GÜNAY, Ramazan AMANVERMEZ, Gökhan KELEŞ

Ankaferd Blood Stopper: Does it have a role in fracture healing?

To examine the effect of Ankaferd Blood Stopper (ABS) on bone healing using a rat femur fracture model. Materials and methods: Eight rats were used as a control group (group 1), which was not subjected to fractures. The remaining 48 rats were divided into 6 groups of 8 each. The femoral shaft fractures were produced by cutting with bone scissors. One milliliter of ABS was applied to the fracture region of groups 3 (day 7), 5 (day 21), and 7 (day 45), or rats treated with saline instead of ABS on the fracture region in groups 2 (day 7), 4 (day 21), and 6 (day 45). After the treatments, blood was taken for analyses and fracture healing was evaluated radiologically according to the modified Lane and Sandhu scoring system on postfracture days 7, 21, and 45. Results: Fracture-hematoma formation interfered with ABS-induced hemostatic protein network or aggregation. Radiological healing scores observed at an average of 50% in group 3 were low compared to group 2 the first week, but fracture healing seemed to be normal at weeks 3 and 6. No statistical difference was observed for bone morphogenetic protein-2 and fibroblast growth factor-2 (FGF-2), alkaline phosphatase, osteocalcin, pyridinoline, and deoxypyridinoline studied among the groups. FGF-2 level in serum decreased by an average of 37.3% and 32.6% in groups 3 and 7, which were treated with ABS, in comparison with groups 2 and 6, respectively. Conclusion: The application of ABS to femur fractures has no extra positive effect on bone union in fracture healing periods, except for bleeding control.

Anahtar Kelimeler:

Key words: Ankaferd, fracture healing, BMP-2, FGF-2, bone formation, resorption markers

Ankaferd Blood Stopper: Does it have a role in fracture healing?

Keywords:

Key words: Ankaferd, fracture healing, BMP-2, FGF-2, bone formation, resorption markers,

PDF

___

1- Ergenoglu MU, Yerebakan H, Kucukaksu DS. A new practical alternative for the control of sterna bleeding during cardiac surgery: Ankaferd Blood Stopper. Heart Surg Forum 2010; 13: E379–80. 2- Huri E, Akgül KT, Yücel MÖ, Astarcı HM, Üstün H, Germiyanoğlu RC. The second step in vitro trial of Ankaferd® Bloodstopper®: comparison with other hemostatic agents. Turk J Med Sci 2011; 41: 7–15. 3- Haznedaroglu BZ, Haznedaroglu IC, Walker SL, Bilgili H, Goker H, Kosar A et al. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper. Clin Appl Thromb Hemost 2010; 16: 446–53. 4- Teker AM, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010; 267: 1377–81. 5- Öztürk MA, Koçak Tufan Z, Demirağ MD, Haznedaroğlu IC. Effects of Ankaferd hemostat on the synovial fluid of patients with osteoarthritis. Turk J Med Sci 2012; 42: 768–72. 6- Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005; 36: 1392–404. 7- Al-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einborn TA. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008; 87: 107–18. 8- Marsell R, Einborn TA. The biology of fracture healing. Injury 2011; 42: 551–5. 9- Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998; 13: 1483–90. 10- Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006; 38: 1424–9. 11- Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 2000; 105: 1085–93. 12- Kawaguchi H, Nakamura K, Tabata Y, Ikada Y, Aoyama I, Anzai J et al. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J Clin Endocrinol Metab 2001; 86: 875–80. 13- Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005; 36: 1392–404. 14- Ohishi T, Takahashi M, Kushida K, Hoshino H, Tsuchikawa T, Naitoh K et al. Changes of biochemical markers during fracture healing. Arch Orthop Trauma Surg 1998; 118: 126–30. 15- Akesson K, Kakönen SM, Josefsson PO, Karlsson MK, Obrant KJ, Pettersson K. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005; 23: 30–5. 16- Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleveland Clin J Med 2008; 75: 739–49. 17- Lane JM, Sandhu HS. Current approaches to experimental bone grafting. Orthop Clin North Am 1987; 18: 213–25. 18- Beyazit Y, Kurt M, Kekilli M, Göker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329–36. 19- İşler SC, Demircan S, Çakarer S, Çebi Z, Keskin C, Soluk M et al. Effects of folk medicinal plant extract Ankaferd Blood Stopper® on early bone healing. J Appl Oral Sci 2010; 18: 409– 20- Amanvermez R, Günay M, Pişkin A, Keleş G, Tomak L. TNF-α, IL-1β, and oxidative stress during fracture healing with or without Ankaferd®. Bratisl Med J 2013, in press. 21- Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Toben D, Schmidmaier G et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 2010; 16: 427–33. 22- Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev 2011; 17: 393–402. 23- Sykaras N, Opperman LA. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J Oral Sci 2003; 45: 57–73. 24- Taniguchi T, Matsumoto T, Shindo H. Changes of serum levels of osteocalcin, alkaline phosphatase, IGF-I and IGF-binding protein-3 during fracture healing. Injury 2003; 34: 477–9. 25- Paskalev M, Krastev S, Filipov J. Changes in some bone markers after experimental fracture and intramedullary osteosynthesis in dogs. Trakia J Sci 2005; 3: 46–50. 26- Cox G, Einborn TA, Tzioupis C, Giannoudis PV. Boneturnover markers in fracture healing. J Bone Joint Surg 2010; 92-B: 329–34.